Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprorelin for Prevention of POF After HSCT
NCT05667428Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Mar 2023
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Randomised, open-label trial of leuprorelin extended-release injection in primary ovarian insufficiency (POI) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Premature Ovarian Failure rate at 3 years. Status: unknown.
02
Drugs
leuprorelin extended-release injection
03
Conditions
primary ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT05667428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667428.